Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.92 -0.09 (-0.19%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
The companies are facing off with their heart drugs in a growing disease area. 
Via Investor's Business Daily
These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio?
Large-cap stocks, such as PDD, PBR, KMX, APTV, STLA, CRWV, BMY, Z, BABA, and YUMC, saw significant declines due to trade tensions and missed earnings. 
Via Benzinga
Topics World Trade
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock.
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
3 Value Stocks in the Doghouse
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
Via Benzinga
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
What's going on in today's session: S&P500 movers
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday?
Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff. 
Via Benzinga
Topics World Trade
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients
The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results. 
Via Benzinga
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Bristol Myers Wins Dismissal Of Class Action Lawsuit Accusing It Of Fraudulently Acquiring Patents – Retail Sentiment Remains Subdued
U.S. District Judge Edgardo Ramos in Manhattan said the plaintiffs failed to show that Bristol Myers and Celgene Corp violated the federal Sherman antitrust law. 
Via Stocktwits
Topics Fraud Government Intellectual Property
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Is Pfizer Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
Laser-Focus on These Tariff-Proof Stocks Before It’s Too Late
Stay calm amid tariff uncertainty with low-valued pharma and European stocks. Discover why these sectors offer protection and potential gains. 
Via InvestorPlace
Topics Government Intellectual Property World Trade
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
Via The Motley Fool
Topics Intellectual Property
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
Is Bristol-Myers Squibb Gaining or Losing Market Support?
Via Benzinga
Beat the S&P 500 With This Cash-Gushing Dividend Stock
Via The Motley Fool
Topics Intellectual Property Stocks
BMY: A High-Yielding Drug Stock With Great Growth Potential
Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer... 
Via Talk Markets
Topics Stocks / Equities
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
5 Ways to Prepare for AI’s ‘Tower of Terror’ Moment
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Artificial Intelligence Economy Government
50-Year-Old Early Retiree Making $175,000 in Dividends Shares Portfolio - 'Now I Spend on Travel, Cars and Doing What I Want'
Via Benzinga
The 5-Letter Word Every Investor Should Memorize to Win in 2025
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Economy World Trade
3 Deeply Discounted Dividend Stocks to Buy Today
Via The Motley Fool
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.